#1 Clinical Trials Search in Europe

Clostridia, Cluster Xiva, Strain Relative Clostridium_Ap Sp000509125, Live

This article explores the ongoing clinical trials of VE202, a promising new drug for treating mild to moderate ulcerative colitis. VE202 is a combination of live bacterial strains being tested in a Phase 2 study to evaluate its efficacy and safety in patients with this inflammatory bowel condition. The trial aims to assess the drug’s ability to improve endoscopic response and overall patient outcomes.

Table of Contents

What is VE202?

VE202 is an investigational drug being studied for the treatment of mild to moderate ulcerative colitis. It is a capsule containing live bacteria from various strains, including Clostridia and Bacilli clusters.[1] These bacteria are part of a group called probiotics, which are live microorganisms that may provide health benefits when consumed in adequate amounts.

Target Condition: Mild to Moderate Ulcerative Colitis

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum. Symptoms can include diarrhea, abdominal pain, and rectal bleeding. The term “mild to moderate” refers to the severity of the condition, which is determined by factors such as the extent of inflammation and the impact on daily life.[1]

How VE202 Works

While the exact mechanism of action is not fully understood, VE202 is designed to introduce beneficial bacteria into the gut. These bacteria may help restore balance to the gut microbiome, which is often disrupted in people with ulcerative colitis. By doing so, it may help reduce inflammation and improve symptoms of the condition.[1]

Current Research on VE202

VE202 is currently being studied in a Phase 2 clinical trial. This means that while it has shown promise in earlier studies, it is still considered experimental and is not yet approved for general use. The main goals of the current study are:

  • To evaluate how effective VE202 is in improving the appearance of the colon lining (endoscopic response) after 8 weeks of treatment
  • To assess the safety of VE202 throughout the study[1]

Eligibility Criteria for the Study

To participate in the VE202 study, patients must meet certain criteria. Some key requirements include:

  • Age between 18 and 75 years
  • Diagnosed with ulcerative colitis at least 3 months before the study
  • Have active mild to moderate ulcerative colitis, as determined by specific medical criteria
  • Have not previously received certain types of treatments for ulcerative colitis, such as biologic agents or JAK inhibitors
  • Not have certain other medical conditions, such as Crohn’s disease or active infections[1]

It’s important to note that these are just some of the criteria. A healthcare provider can provide more detailed information about eligibility for the study.

Potential Benefits of VE202

If proven effective, VE202 could offer several potential benefits for people with mild to moderate ulcerative colitis:

  • Improvement in symptoms such as diarrhea and rectal bleeding
  • Reduction in inflammation of the colon lining
  • A new treatment option for those who haven’t responded well to other therapies
  • Potentially fewer side effects compared to some existing treatments, as it uses naturally occurring bacteria[1]

Safety Considerations

As with any investigational treatment, there are potential risks and side effects associated with VE202. The current study is carefully monitoring for any adverse events, particularly those that might be related to the treatment. Some safety measures in the study include:

  • Regular check-ups and monitoring throughout the study period
  • Careful screening of participants to ensure they’re suitable for the treatment
  • Exclusion of people with certain conditions or those taking certain medications that might interact with VE202[1]

It’s important to remember that VE202 is still in the research phase, and more information about its safety and effectiveness will become available as the study progresses.

Aspect Details
Drug Name VE202 (JNJ-72537634)
Condition Treated Mild to moderate ulcerative colitis
Trial Phase Phase 2
Study Design Randomized, Double-Blind, Placebo-Controlled
Primary Endpoint Endoscopic response rate at Day 56
Treatment Duration 8 weeks
Key Inclusion Criteria Adults 18-75 years, UC diagnosis for ≥3 months, active mild to moderate disease
Key Exclusion Criteria History of Crohn’s disease, recent antibiotic use, active infections
Safety Monitoring Grade ≥3 treatment-related adverse events, serious adverse events

FAQ

  • What is VE202 and how does it work? VE202 is a capsule containing multiple strains of live bacteria, including various Clostridia and Bacilli species. It is designed to help restore balance to the gut microbiome, which may play a role in reducing inflammation and improving symptoms in ulcerative colitis patients.
  • Who is eligible to participate in this clinical trial? The trial is open to adults aged 18-75 with a documented diagnosis of mild to moderate ulcerative colitis for at least 3 months. Participants must have active disease, as defined by specific criteria, and should not have previously received certain types of treatments for their condition.
  • What is the main goal of this clinical trial? The primary objective is to evaluate the efficacy of VE202 in terms of endoscopic response after 8 weeks of treatment. This is measured by a reduction in the Mayo endoscopic subscore, which assesses the appearance of the colon during a flexible sigmoidoscopy examination.
  • How long does the treatment last in this study? The treatment period in this study lasts for 8 weeks. During this time, participants will receive either VE202 or a placebo, and their response to the treatment will be monitored through various assessments, including endoscopic examinations.
  • What are the potential benefits and risks of participating in this trial? Potential benefits include access to a novel treatment that may improve ulcerative colitis symptoms. However, as with any clinical trial, there are potential risks, including possible side effects from the study drug. The trial is designed to carefully monitor participants' safety, with a focus on identifying any treatment-related adverse events.

Ongoing Clinical Trials on Clostridia, Cluster Xiva, Strain Relative Clostridium_Ap Sp000509125, Live

  • Study on VE202 for Patients with Mild-to-Moderate Ulcerative Colitis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Hungary Lithuania The Netherlands Poland

Glossary

  • Ulcerative Colitis: A chronic inflammatory bowel disease that affects the lining of the large intestine (colon) and rectum, causing inflammation and ulcers.
  • Endoscopic Response: An improvement in the appearance of the colon as seen during an endoscopic examination, typically indicating a reduction in inflammation and ulceration.
  • Mayo Endoscopic Subscore: A scoring system used to assess the severity of ulcerative colitis based on the appearance of the colon during an endoscopic examination.
  • Flexible Sigmoidoscopy: A medical procedure that allows doctors to examine the lower part of the large intestine using a flexible, lighted tube.
  • Microbiome: The collection of microorganisms, including bacteria, that live in and on the human body, particularly in the gut.
  • Placebo: An inactive substance that looks like the drug being tested but contains no active ingredients, used to compare the effects of the real drug.
  • Phase 2 Clinical Trial: A stage of drug testing that aims to assess the effectiveness and safety of a new treatment in a larger group of patients with the target condition.
  • Colony Forming Unit (CFU): A measure used to estimate the number of viable bacteria or fungal cells in a sample.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. http://clinicaltrials.eu/trial/study-on-ve202-for-patients-with-mild-to-moderate-ulcerative-colitis/